Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation
ConcePTION logo


Start Date
End Date
IMI2 - Call 13
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
15 299 991
EFPIA in kind
13 387 500
90 916
Total Cost
28 778 407


Women who are pregnant or breastfeeding are traditionally excluded from medical research due to safety concerns. As a result of this, only 5 % of medications have adequate safety information on their use in pregnant or breastfeeding women, and this makes it very hard for doctors and women to make informed decisions about their treatment. Nonetheless, some 90 % of women are exposed to a prescription medication at some point during their pregnancy. The ultimate goal of ConcePTION is to create a trusted biomedical ecosystem capable of providing evidence-based information on the safety of medications during pregnancy and breastfeeding in an efficient, systematic and ethically responsible way. The information will be provided in a form that is usable by both healthcare providers and patients alike. The project will achieve this in a number of ways. Firstly, it will improve and unify existing approaches to data collection in this area by re-using existing, de-identified data generated during routine patient care. The project also aims to deliver procedures and tools for the collection of digital data and samples directly from pregnant women. They will also create the first Europe-wide breast milk biobank for research purposes, and develop tools to predict which drugs are likely to be transferred to breast milk. Finally, the team will establish a web-based drug information knowledge bank.

Participants Show participants on map

EFPIA companies
  • Abbvie Inc, North Chicago, Illinois, United States
  • Bristol-Myers Squibb Company Corp, Princeton, NJ, United States
  • Covance Laboratories LTD, Harrogate, United Kingdom
  • Eli Lilly and Company Limited, Basingstoke, United Kingdom
  • Ellegaard Gottingen Minipigs As, Dalmose, Denmark
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany
  • Novartis Pharma AG, Basel, Switzerland
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
  • Takeda Development Centre Europe LTD., London, United Kingdom
  • Teva Pharmaceutical Industries Limited, Netanya, Israel
  • UCB Biopharma SPRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Groningen, Groningen, Netherlands
  • Agenzia Regionale Di Sanita, Firenze, Italy
  • Alma Mater Studiorum - Universita Di Bologna, Bologna, Italy
  • Biobanks And Biomolecular Resourcesresearch Infrastructure Consortium(Bbmri-Eric), Graz, Austria
  • Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 09, France
  • Consiglio Nazionale Delle Ricerche, Roma, Italy
  • European Forum For Good Clinical Practice, Brussels, Belgium
  • European Institute Of Women'S Health Company Limited By Guarantee, Dublin, Ireland
  • Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana, Valencia, Spain
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • Karolinska Institutet, Stockholm, Sweden
  • Katholieke Universiteit Leuven, Leuven, Belgium
  • Medicines And Healthcare Products Regulatory Agency, London, United Kingdom
  • Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands
  • St George'S Hospital Medical School, London, United Kingdom
  • Stichting Entis (European Network Teratology Information Services) Foundation, Hertogenbosch, Netherlands
  • Stichting Lareb, 's Hertogenbosch, Netherlands
  • Stockholms Lans Landsting, Stockholm, Sweden
  • Swansea University, Swansea, United Kingdom
  • Terveyden Ja Hyvinvoinnin Laitos, Helsinki, Finland
  • The European Institute For Innovation Through Health Data, Gent, Belgium
  • The European Medicines Agency, Canary Wharf, London, United Kingdom
  • The Newcastle Upon Tyne Hospitals Nhs Foundation Trust, Newcastle-Upon-Tyne, United Kingdom
  • The University Of Manchester, Manchester, United Kingdom
  • Universita Degli Studi Di Ferrara, Ferrara, Italy
  • Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
  • Universite De Geneve, Genève 4, Switzerland
  • Universitetet I Oslo, Oslo, Norway
  • University Of Kwazulu-Natal, Westville, South Africa
  • University Of Ulster, Coleraine, United Kingdom
  • Uppsala Universitet, Uppsala, Sweden
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Bionotus, Temse, Belgium
  • Elevate BV, Utrecht, Netherlands
  • Orcion BV, Asten, Netherlands
  • The Synergist, Bruxelles, Belgium
  • Ttopstart BV, Bilthoven, Netherlands
Third parties
  • Izmir Katip Celebi Universitesi, Izmir, Turkey
  • Masarykova univerzita, Brno, Czech Republic
  • Medizinische Universitat Graz, Graz, Austria
  • Ministry Of Health, Jerusalem, Israel
  • Odense Universitetshospital, Odense, Denmark
  • Synergist Services, Bruxelles, Belgium
  • Universitaet Leipzig, Leipzig, Germany
  • Uniwersytet Medyczny Im Piastow Slaskich We Wroclawiu, Wroclaw, Poland


Project coordinator